# OnCo record b-all-cytogenetic-risk (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/b-all-cytogenetic-risk/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "b-all-cytogenetic-risk" ;
  schema:name "B-ALL risk groups (NCI criteria, ETV6::RUNX1, hyperdiploidy, hypodiploidy, iAMP21, IKZF1, CNS status)"@en ;
  schema:alternateName "NCI risk criteria"@en, "NCI standard risk"@en, "NCI high risk"@en, "Rome/NCI criteria"@en, "ETV6::RUNX1"@en, "ETV6-RUNX1"@en, "TEL-AML1"@en, "t(12;21)"@en, "high hyperdiploidy"@en, "hyperdiploid ALL"@en, "trisomies 4 and 10"@en, "hypodiploidy"@en, "hypodiploid ALL"@en, "low hypodiploidy"@en, "near-haploid ALL"@en, "iAMP21"@en, "intrachromosomal amplification of chromosome 21"@en, "IKZF1 deletion"@en, "IKZF1-plus"@en, "IKZF1plus"@en, "TCF3::PBX1"@en, "t(1;19)"@en, "TCF3::HLF"@en, "DUX4-rearranged ALL"@en, "PAX5-altered ALL"@en, "CNS status"@en, "CNS1"@en, "CNS2"@en, "CNS3"@en, "prednisone response"@en, "day 8 prednisone response"@en, "day 29 MRD"@en ;
  schema:description "Childhood leukaemia treatment is chosen from a risk table built over fifty years: age and white count at diagnosis (the NCI criteria), the chromosome pattern in the blasts (favourable ETV6::RUNX1 and high hyperdiploidy, unfavourable hypodiploidy, iAMP21, KMT2A, Ph-positive and Ph-like), whether leukaemia cells are in the spinal fluid, and above all how fast the leukaemia clears in the first month."@en ;
  schema:url <https://onco.cc/terms/b-all-cytogenetic-risk/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  onco:related <https://onco.cc/terms/cytogenetics/>, <https://onco.cc/terms/fish/>, <https://onco.cc/terms/philadelphia-chromosome/>, <https://onco.cc/terms/ph-like-all/>, <https://onco.cc/targets/kmt2a/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/terms/li-fraumeni/>, <https://onco.cc/technologies/tpmt-nudt15-genotyping/>, <https://onco.cc/drugs/mercaptopurine/> ;
  onco:cancers <https://onco.cc/cancers/all-paediatric-standard-risk/>, <https://onco.cc/cancers/all-paediatric-high-risk/>, <https://onco.cc/cancers/all-paediatric-ph-positive/>, <https://onco.cc/cancers/all-ph-like/>, <https://onco.cc/cancers/all-infant/>, <https://onco.cc/cancers/all-paediatric-relapsed/>, <https://onco.cc/cancers/all-leukemia/> .